ventral tegmental area

**Location/anatomy:** Medial midbrain (mesencephalon), near the interpeduncular fossa, medial to the substantia nigra pars compacta (SNc) and adjacent to the red nucleus. Contains mostly dopaminergic neurons (~60-65%), plus GABAergic (~30%) and glutamatergic neurons.

**Pathways (A10 dopamine cell group):** - **Mesolimbic pathway:** VTA → nucleus accumbens (ventral striatum), amygdala, hippocampus. Mediates reward, reinforcement, motivation, and pleasure. Hyperactivity → *positive symptoms of schizophrenia* (hallucinations, delusions). - **Mesocortical pathway:** VTA → prefrontal cortex (especially dorsolateral and ventromedial). Involved in executive function, cognition, and motivation. Hypoactivity → *negative symptoms of schizophrenia* (flat affect, avolition, alogia) and cognitive deficits. - Contrast with the **nigrostriatal pathway** (SNc → dorsal striatum; motor control; degeneration in Parkinson disease) and the **tuberoinfundibular pathway** (hypothalamic arcuate nucleus → anterior pituitary; dopamine inhibits prolactin).

**Addiction:** Nearly all drugs of abuse increase dopamine release in the nucleus accumbens via the VTA: - Cocaine and amphetamines: block DAT reuptake / reverse transport and increase release. - Opioids: inhibit GABAergic interneurons in the VTA (disinhibition), increasing dopamine neuron firing. - Nicotine: activates nicotinic ACh receptors on VTA neurons. - Alcohol and cannabinoids: also enhance VTA dopaminergic activity. The VTA-nucleus accumbens circuit is the core of the "reward pathway."

**Clinical correlates and pharmacology:** - *Schizophrenia:* the dopamine hypothesis. Mesolimbic hyperactivity (positive symptoms) and mesocortical hypoactivity (negative symptoms). Antipsychotics block D2 receptors, which treats positive symptoms but may worsen negative symptoms and cause extrapyramidal effects (nigrostriatal blockade) and hyperprolactinemia (tuberoinfundibular blockade). Atypical antipsychotics (5-HT2A antagonism) may help the mesocortical deficit. - *Depression/anhedonia:* reduced VTA-accumbens reward signaling. Bupropion (NE/DA reuptake inhibitor) can help with anhedonia and smoking cessation. - *Parkinson disease:* primarily SNc loss, but VTA neurons are relatively spared early on (the VTA is less affected than the SNc). - *Reward prediction error:* VTA dopamine neurons fire to unexpected rewards and encode prediction errors (learning and reinforcement).

**Receptors/signaling:** D1-like receptors (D1, D5) are Gs-coupled (↑cAMP). D2-like receptors (D2, D3, D4) are Gi-coupled (↓cAMP). Dopamine is synthesized from tyrosine → L-DOPA (tyrosine hydroxylase, the rate-limiting step) → dopamine (DOPA decarboxylase) and degraded by MAO and COMT to HVA.

**High-yield pearl:** VTA = "reward" (mesolimbic) + "cognition" (mesocortical). SNc = "movement." Know which pathway each antipsychotic or Parkinson drug side effect corresponds to.